AR085291A1 - Metodos para sintetizar derivados del precursor z de molibdopterina - Google Patents

Metodos para sintetizar derivados del precursor z de molibdopterina

Info

Publication number
AR085291A1
AR085291A1 ARP120100560A ARP120100560A AR085291A1 AR 085291 A1 AR085291 A1 AR 085291A1 AR P120100560 A ARP120100560 A AR P120100560A AR P120100560 A ARP120100560 A AR P120100560A AR 085291 A1 AR085291 A1 AR 085291A1
Authority
AR
Argentina
Prior art keywords
compound
formula
prepare
molibdopterine
synthetizing
Prior art date
Application number
ARP120100560A
Other languages
English (en)
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of AR085291A1 publication Critical patent/AR085291A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)

Abstract

Estos compuestos son de utilidad para tratar trastornos asociados con deficiencia de cofactor de molibdeno. Composiciones farmacéuticas e intermediarios.Reivindicación 1: Un proceso para preparar un compuesto de la fórmula (1) o una de sus sales farmacéuticamente aceptables, donde el proceso comprende: (a) hacer reaccionar un compuesto de la fórmula (2) con un compuesto de la fórmula (3) para producir un compuesto de la fórmula (4), en donde: cada R1 es, de modo independiente, H o un grupo protector; (b) proteger selectivamente el compuesto de la fórmula (4) para preparar un compuesto de la fórmula (5); (c) fosforilar el compuesto de la fórmula (5) para preparar un compuesto de la fórmula (6); (d) oxidar el compuesto de la fórmula (6) para preparar un compuesto de la fórmula (7); y (e) desproteger el compuesto de la fórmula (7) para preparar el compuesto de la fórmula (1). Reivindicación 38: Un proceso para preparar un compuesto de la fórmula (8) o una de sus formas salinas farmacéuticamente aceptables, donde el proceso comprende: (a) hacer reaccionar un compuesto de la fórmula (2) con un compuesto de la fórmula (3) para producir un compuesto de la fórmula (4), en donde: cada R1 es, de modo independiente, H o un grupo protector; (b) proteger selectivamente el compuesto de la fórmula (4) para preparar un compuesto de la formula (5); (c) fosforilar el compuesto de la fórmula (5) para preparar un compuesto de la fórmula (6); (d) oxidar el compuesto de la fórmula (6) para preparar un compuesto de la fórmula (9); y (e) desproteger el compuesto de la fórmula (9) para preparar el compuesto de la fórmula (8).
ARP120100560A 2011-02-18 2012-02-17 Metodos para sintetizar derivados del precursor z de molibdopterina AR085291A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161444280P 2011-02-18 2011-02-18
US201161444399P 2011-02-18 2011-02-18
US201161444389P 2011-02-18 2011-02-18
US201161498808P 2011-06-20 2011-06-20
US201161498801P 2011-06-20 2011-06-20
US201261599314P 2012-02-15 2012-02-15

Publications (1)

Publication Number Publication Date
AR085291A1 true AR085291A1 (es) 2013-09-18

Family

ID=46672966

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100560A AR085291A1 (es) 2011-02-18 2012-02-17 Metodos para sintetizar derivados del precursor z de molibdopterina

Country Status (16)

Country Link
US (2) US9260462B2 (es)
EP (1) EP2675278B1 (es)
JP (1) JP5972911B2 (es)
KR (1) KR20140007431A (es)
AR (1) AR085291A1 (es)
AU (1) AU2012219292B2 (es)
BR (1) BR112013020864A2 (es)
CA (1) CA2827679C (es)
CO (1) CO7071121A2 (es)
EA (1) EA201391206A1 (es)
ES (1) ES2569252T3 (es)
IL (1) IL227917A0 (es)
MX (1) MX2013009501A (es)
SG (1) SG192826A1 (es)
TW (1) TW201241005A (es)
WO (1) WO2012112922A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9260462B2 (en) 2011-02-18 2016-02-16 Alexion Pharmaceuticals, Inc. Methods for synthesizing molybdopterin precursor Z derivatives
WO2016115473A1 (en) * 2015-01-15 2016-07-21 Mayo Foundation For Medical Education And Research Methods of treating neurological inflammatory disorders
WO2017019532A1 (en) 2015-07-24 2017-02-02 Alexion Pharmaceuticals, Inc. Precursor z (cpmp) to treat molybdenum cofactor deficiency type a
EP3394056B1 (en) 2015-12-22 2021-04-14 Shy Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
CA3066939A1 (en) 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
EP4532221A1 (en) 2022-05-27 2025-04-09 ARLANXEO Deutschland GmbH Rubber compounds of functionalized conjugated diene rubbers and silica fillers

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CA1262347A (en) 1985-01-28 1989-10-17 Suntory Limited Preparation process of (6r)-tetrahydro-l-biopterin
AU1824101A (en) * 1999-06-18 2001-01-09 Elitra Pharmaceuticals, Inc. Nucleotide sequences of moraxella catarrhalis genome
DE60105023T2 (de) 2000-06-28 2005-08-18 Smithkline Beecham P.L.C., Brentford Nassvermahlungsverfahren
US20030207430A1 (en) * 2001-03-01 2003-11-06 Tang Y. Tom Human enzyme molecules
DE102004004642A1 (de) * 2004-01-29 2006-04-27 Schwarz, Guenter, Dr. Produktion, Gewinnung und therapeutischer Einsatz des Molybdopterin-Derivats Precursor Z zur Therapie der Stoffwechselerkrankung humaner Molybdäncofaktor-Defizienz und anderer assoziierter Krankheiten
WO2007052308A2 (en) 2005-11-03 2007-05-10 Brain N' Beyond Biotech Pvt. Ltd. Glyco-phosphorylated biologically active agents
JP2010515747A (ja) 2007-01-12 2010-05-13 ビオマリン プハルマセウトイカル インコーポレイテッド テトラヒドロビオプテリンプロドラッグ
US7888506B2 (en) * 2007-01-26 2011-02-15 Duquesne University Of The Holy Spirit Composition, synthesis, and use of a new class of fluorophores
CA2711444C (en) 2008-01-07 2017-12-12 Biomarin Pharmaceutical Inc. Method of synthesizing tetrahydrobiopterin
CN101959870B (zh) * 2008-02-26 2013-10-16 桑多斯股份公司 吗啉衍生物的制备
US9260462B2 (en) 2011-02-18 2016-02-16 Alexion Pharmaceuticals, Inc. Methods for synthesizing molybdopterin precursor Z derivatives

Also Published As

Publication number Publication date
US20140323726A1 (en) 2014-10-30
MX2013009501A (es) 2014-02-03
SG192826A1 (en) 2013-09-30
TW201241005A (en) 2012-10-16
JP5972911B2 (ja) 2016-08-17
CA2827679A1 (en) 2012-08-23
EP2675278A4 (en) 2014-08-20
WO2012112922A1 (en) 2012-08-23
US9260462B2 (en) 2016-02-16
CO7071121A2 (es) 2014-09-30
BR112013020864A2 (pt) 2019-09-24
AU2012219292B2 (en) 2015-03-05
EA201391206A1 (ru) 2014-02-28
IL227917A0 (en) 2013-09-30
JP2014510054A (ja) 2014-04-24
EP2675278B1 (en) 2016-02-17
NZ614009A (en) 2014-08-29
ES2569252T3 (es) 2016-05-09
KR20140007431A (ko) 2014-01-17
EP2675278A1 (en) 2013-12-25
CA2827679C (en) 2020-06-02
AU2012219292A1 (en) 2013-03-14
US20140303367A1 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
AR085291A1 (es) Metodos para sintetizar derivados del precursor z de molibdopterina
CO2018012171A2 (es) Piridinas sustituidas con heteroarilo y métodos de uso
EA202090917A1 (ru) Получение псилоцибина, различных полиморфных форм, промежуточных соединений, составов и их применение
JOP20190070A1 (ar) مركبات بنزو[b] ثيوفين كناهضات محفزة لبروتين جينات الإنترفيرون
UY37900A (es) Nuevos derivados de rapamicina
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
CO6700837A2 (es) Proceso de elaboración para derivados de prrimidina
UY32025A (es) Derivados sustituídos de la 6-cloro-2-hidroxi-3-(3,4-dioxo-ciclobut-1-enil-amino)-n-metoxi-n-metil-bencen-sulfonamida, solvatos, hidratos o sales farmacéuticamente aceptables de los mismos, proceso de preparación, composiciones y aplicaciones.
MD4820B1 (ro) Compuşi dihidroizochinolinonici substituiţi
UY33557A (es) Inhibidores de oxadiazol de la produccion de leucotrieno
UY35012A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
MX2018000280A (es) Oxiesteroles y metodos de uso de los mismos.
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
CO2020007222A2 (es) Proceso para la preparación de derivados antihelmínticos de 4-amino-quinolin-3-carboxamida
MX2019003026A (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
MY182353A (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MX2020001157A (es) Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc).
MX2019009764A (es) Procesos para preparar acido 3-(3-(3,5-dimetil-1h-pirazol-4-il)pro poxi)-4- 5-fluorobenzoico (ag-10), sus compuestos intermedios, y sales del mismo.
UY36746A (es) Método para la síntesis de derivados de rapamicina
UY37932A (es) Proceso para producir compuestos de piridazinona herbicidas
MX377644B (es) 6.7.beta-epóxidos esteroideos como intermedios químicos.
MX2017015662A (es) Procesos para la preparacion de derivados acidos de n-acetilgalactosamina (galnac).
MX2016002718A (es) Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc).
PY1515461A (es) Derivados de Dihidropirrolopirimidina
AR086987A1 (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia

Legal Events

Date Code Title Description
FB Suspension of granting procedure